Cellular, Molecular and Behavioural Neuroscience Lab

Journal article

N. J. Dar, S. Bhat, M. Rehman, A. Booker
Frontiers in Pharmacology, 2023

Semantic Scholar DOI PubMedCentral PubMed

Cite

APA Click to copy
Dar, N. J., Bhat, S., Rehman, M., & Booker, A. (2023). Editorial: Investigating the molecular targets and therapeutic potential of Withania somnifera (Ashwagandha) in various pathophysiological conditions. Frontiers in Pharmacology.

Chicago/Turabian Click to copy
Dar, N. J., S. Bhat, M. Rehman, and A. Booker. “Editorial: Investigating the Molecular Targets and Therapeutic Potential of Withania Somnifera (Ashwagandha) in Various Pathophysiological Conditions.” Frontiers in Pharmacology (2023).

MLA Click to copy
Dar, N. J., et al. “Editorial: Investigating the Molecular Targets and Therapeutic Potential of Withania Somnifera (Ashwagandha) in Various Pathophysiological Conditions.” Frontiers in Pharmacology, 2023.

BibTeX Click to copy

@article{n2023a,
  title = {Editorial: Investigating the molecular targets and therapeutic potential of Withania somnifera (Ashwagandha) in various pathophysiological conditions},
  year = {2023},
  journal = {Frontiers in Pharmacology},
  author = {Dar, N. J. and Bhat, S. and Rehman, M. and Booker, A.}
}

Abstract

cancer, neurodegenerative diseases, in ﬂ ammatory and respiratory disorders. The study by Singh et al demonstrates that Withania somnifera can be used as an add-on therapy for COPD patients. Chronic obstructive pulmonary disease (COPD) is a common and debilitating lung disease, and patients with COPD are at higher risk of severe outcomes from COVID-19. Current therapies for COPD lack disease-modifying potential and can cause adverse side effects. The study is a randomized, double-blind, placebo-controlled clinical trial involving 150 COPD patients. The results show that patients in the WS group have signi ﬁ cantly improved lung function, quality of life, exercise tolerance